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Abstract
Background: Diabetes mellitus is a leading cause of morbidity and mortality worldwide. Studies have shown that
Zinc has numerous beneficial effects in both type-1 and type-2 diabetes. We aim to evaluate the literature on the
mechanisms and molecular level effects of Zinc on glycaemic control, β-cell function, pathogenesis of diabetes and
its complications.
Methods: A review of published studies reporting mechanisms of action of Zinc in diabetes was undertaken in
PubMed and SciVerse Scopus medical databases using the following search terms in article title, abstract or keywords;
(“Zinc” or “Zn”) and (“mechanism” or “mechanism of action” or “action” or “effect” or “pathogenesis” or “pathology” or
“physiology” or “metabolism”) and (“diabetes” or “prediabetes” or “sugar” or “glucose” or “insulin”).
Results: The literature search identified the following number of articles in the two databases; PubMed (n = 1799) and
SciVerse Scopus (n = 1879). After removing duplicates the total number of articles included in the present review is 111.
Our results show that Zinc plays an important role in β-cell function, insulin action, glucose homeostasis and the
pathogenesis of diabetes and its complications.
Conclusion: Numerous in-vitro and in-vivo studies have shown that Zinc has beneficial effects in both type-1 and type-2
diabetes. However further randomized double-blinded placebo-controlled clinical trials conducted for an adequate
duration, are required to establish therapeutic safety in humans.
Introduction
Diabetes mellitus is a leading cause of morbidity and
mortality worldwide, with an estimated 387 million
adults being affected in year 2014, a figure which is ex-
pected to increase by nearly 40 % by year 2035 [1].
Ninety to ninety five percent of those with the disease
have type-2 diabetes. In a patho-physiologic sense, type-
2 diabetes is a multi-organ, multi-factorial condition
characterized primarily by insulin resistance, hyper insu-
linaemia and β-cell dysfunction, which ultimately leads
to β-cell failure [2]. Type-1 diabetes has historically been
most prevalent in populations of European origin, and
the latest edition of the Diabetes Atlas estimates that
490,100 children below the age of 15 years are living
with type-1 diabetes [1]. Currently 77 % of those with
diabetes live in low- and middle-income countries of the
African, Asian, and South American regions [1, 3, 4]. In
2014, diabetes was responsible for 4.9 million deaths
worldwide and at least US$ 612 billion in global health-
care expenditures (11 % of the total global healthcare ex-
penditures in adults) [1]. Recent cost estimates, include
those for Brazil (US$ 3.9 billion), Argentina (US$ 0.8
billion) and Mexico (US$ 2.0 billion) [5]. Each of these is
an annual figure and is rising as diabetes prevalence in-
creases. Overall, direct health care costs of diabetes ranges
from 2.5 to 15 % annual health care budgets, depending
on local diabetes prevalence and the sophistication of the
treatment available [5]. Diabetes is also associated with a
host of potentially disabling macro- and micro-vascular
complications. Hence, there is also a much larger burden
in the form of lost productivity as a result of restricted
daily activity. This rapidly increasing prevalence is attrib-
utable to population growth, aging, urbanization, un-
healthy dietary habits, increasing prevalence of obesity
and physical inactivity [6].
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Although comprehensive diabetes management guide-
lines are readily available, even in developed countries
like the US 30–50 % adults with diabetes do not meet
individualized targets for glycaemic, blood pressure, or
lipid control [7]. Reasons for failure to achieve glycaemic
control includes the progression of underlying β-cell
dysfunction, incomplete adherence to treatment (often
due to adverse effects of medication) and reluctance of
clinicians to intensify therapy [8]. Anti-diabetic agents
currently in use can directly or indirectly enhance the
functioning of β-cells. However, reducing the decline
and the eventual failure of β-cells is crucial in preventing
type-2 diabetes in those at risk and halting disease pro-
gression in the affected patients [8]. The increasing
worldwide prevalence of type-2 diabetes and the pro-
gressive loss of metabolic control in patients are clear
demonstrations that the current therapeutic strategies
aimed at protecting the β-cells are largely inadequate.
Hence there is an urgent need for anti-diabetic agents
targeting the intimate mechanisms of β-cell damage and
optimizing its function at cellular level.
Insulin, is stored as a hexamer containing two Zinc
ions in β-cells of the pancreas and released into the por-
tal venous system at the time of β-cell de-granulation
[9]. In-vitro and in-vivo studies in animals and humans
have shown that Zinc has numerous beneficial effects in
both type-1 and type-2 diabetes [10–14]. A recent meta-
analysis confirmed these findings, and concluded that
Zinc supplementation in patients with diabetes improves
glycaemic control and promotes healthy lipid parameters
[15]. Hence, it is evident that Zinc has a promising po-
tential as a novel therapeutic agent in diabetes. Studies
have also shown that diabetes is commonly accompanied
by hypozincemia and hyperzincuria [16, 17]. Further-
more the high prevalence of Zinc deficiency in develop-
ing countries could be contributing towards driving the
current diabetes epidemic encountered by them [4, 18].
Numerous research studies have been conducted to clar-
ify the molecular mechanisms underlying the action of
Zinc in diabetes. Understanding the molecular mecha-
nisms of action of Zinc will help to further develop tar-
geted therapy and guide future research. The present
study aims to systematically evaluate the literature on
the mechanisms and molecular level effects of Zinc on
glycaemic control, β-cell function, pathogenesis of dia-
betes and its complications.
Methods
A systematic review of published studies reporting mecha-
nisms of action of Zinc in diabetes was undertaken in
accordance with the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) state-
ment (Additional file 1).
Search strategy
A comprehensive search of the literature was conducted
in the PubMed® (U.S. National Library of Medicine,
USA) and SciVerse Scopus® (Elsevier Properties S.A,
USA) databases for studies published before 31st July
2015. During the first stage the above databases were
searched using the following search terms in article title,
abstract or keywords; (“Zinc” or “Zn”) and (“mechanism”
or “mechanism of action” or “action” or “effect” or
“pathogenesis” or “pathology” or “physiology” or “metab-
olism”) and (“diabetes” or “prediabetes” or “sugar” or
“glucose” or “insulin”).
In the second stage the total hits obtained from
searching these three databases were pooled together
and duplicates were removed. This was followed by
screening of the retrieved articles by reading the article
title in the third and abstracts in fourth stage. In the
fifth stage individual manuscripts were screened, and
those not satisfying inclusion criteria (given below)
were excluded. This search process was conducted in-
dependently by two reviewers (PR and SP) and the final
group of articles to be included in the review was deter-
mined after an iterative consensus process.
Inclusion/exclusion criteria and data extraction
The following inclusion criteria were used; a) In-vitro or
in-vivo studies reporting effect of Zinc on diabetes/pre-
diabetes, evaluating effects of Zinc on sugar/glucose, in-
sulin and/or related metabolic parameters, evaluating
the effects of Zinc on pathogenesis and/or complication
of diabetes b) Published in English, or with detailed
summaries in English and c) Peer-reviewed fully pub-
lished research papers. Conference proceedings, edito-
rials, commentaries, review articles and book chapters/
book reviews were excluded.
Data were extracted from the included studies by one
reviewer using a standardized form and checked for ac-
curacy by a second reviewer. The data extracted from
each study were: a) study details (lead author, year pub-
lished/year of survey, type of study—In-vitro/In-vivo), b)
methods (study design, sample size, duration) and c)
mechanism of action data. Discrepancies in the extracted
data were resolved by discussion, with involvement of a
third reviewer when necessary.
Results
The literature search using the above search criteria
identified the following number of articles in the two
databases; Medline® (n = 1799) and SciVerse Scopus®
(n = 1879). After removing duplicates the total number
of articles included in the present review is 111. The
search strategy is summarized in Fig. 1.
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Anti-oxidant properties
Anti-oxidant properties of Zinc have been evaluated in-
vitro, as well as in-vivo animal and human studies. Hypo-
zincaemia and hyperzincuria is known to be present in
patients with both type-1 and type-2 diabetes, and Zinc
supplementation is known to be helpful in restoring
plasma Zinc levels to normal [11, 19–21]. Plasma Thiobar-
bituric acid reactive substances (TBARS), a marker of oxi-
dative stress is high in both type-1 and type-2 diabetic
patients, and significantly decreased by supplementation
of Zinc 30 mg/day for 3–6 months [11, 19]. Selenium-
dependent glutathione peroxidase (Se-GPx), an anti-
oxidant enzyme was also low at baseline in patients with
type-1 diabetes, and was normalized after Zinc supple-
mentation [11]. However, no significant difference in anti-
oxidant metallo-enzyme activity was observed in patients
with type-2 diabetes [19]. Plasma Zinc levels are known to
be negatively correlated with the TBARS levels in both
obese and non-obese patients with type-2 diabetes [22].
In animal models of insulin resistance, Zinc supplemen-
tation is known to enhance insulin sensitivity and antioxi-
dant status [23, 24]. Furthermore, in diabetes induced
animal models anti-oxidant enzymes catalase, GPx and
super-oxide dismutase (SOD) are decreased than in
normal animals [25–27]. Zinc supplementation in these
animals restored the enzyme activity and increased gluta-
thione synthesis [25–27]. Plasma malondialdehyde (MDA)
levels, an index of lipid peroxidation was increased in
diabetic animals and significantly decreased following Zinc
supplementation [26, 28]. When rats were simultaneously
treated with a single injection of alloxan and ZnCl2, the
increase in blood glucose concentration induced by al-
loxan was significantly reduced at 24, 48, and 72 h post-
treatment with ZnCl2 [29]. ZnCl2 injection also increased
the retinal, pancreatic, and liver glutathione and reduced
the TBARS content in comparison with the alloxan-
treated group [29]. Zinc supplementation or injection is
also known to cause a significant induction of anti-
oxidant metallothionein (MT) protein synthesis in the
pancreatic islets, kidneys, liver and heart of diabetes-
induced animals [27, 28, 30–34].
A significant increase in cardiac morphological impair-
ment, fibrosis, and dysfunction is seen in diabetic mice,
which is reversed by Zinc [33]. Cultured cardiac cells
that were directly exposed to high levels of glucose (HG)
and free fatty acid (FFA), treatment that mimics dia-
betes, resulted in reduced cell survival rate, which was
reversed by Zinc [33]. Furthermore, when MT expression
was silenced with the use of MT small-interfering RNA,
the preventive effect of pretreatment with Zinc was abol-
ished [33]. Hence, the prevention of diabetic cardiomyop-
athy by Zinc supplementation is predominantly mediated
by an increase in cardiac MT and the resultant anti-
oxidant effects [33, 35]. Diabetes-induced renal oxidative
damage, inflammation and up-regulated expression of
pro-fibrosis mediators were also markedly attenuated by
Fig. 1 Summarized search strategy
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Zinc supplementation, mediated via the expression of MT
[27, 36]. In-vivo studies in diabetes induced rats have
shown that Zinc has a protective effect against diabetes
induced peripheral nerve damage by stimulating MT
synthesis and reducing oxidative stress [37].
Diabetes induced a significant increase in aortic oxida-
tive damage, inflammation, and remodeling in mice (in-
creased fibrosis and wall thickness) [38]. Zinc treatment
of these diabetic mice completely prevented the above
pathogenic changes in the aorta, and also significantly
up-regulated the expression and function of nuclear fac-
tor (erythroid-derived 2)-like 2 (Nrf2), a pivotal regulator
of anti-oxidative mechanisms, and the expression of MT
[38]. The same up-regulation of Nrf2 by Zinc has been
demonstrated in human renal tubule cells in-vitro and
mouse kidney in-vivo under the diabetic conditions [39].
In cultured renal tubular epithelial cells (NRK-52E), Zinc
supplementation inhibited high glucose induced cell apop-
tosis by attenuating reactive oxygen species production,
facilitated via Nrf2 up-regulation [40]. In postmenopausal
women with type-2 diabetes Zinc supplementation in-
creases TNF-α gene expression, suggesting a close inter-
action between Zinc homeostasis, oxidative stress and
inflammation [41].
Effects on carbohydrate and lipid metabolism
Zinc is known to stimulate glycolysis and inhibit gluco-
neogenesis, an effect that is not overcome by the presence
of glucagon [42–44]. In-vitro studies have demonstrated
that Zinc increases the activity of glycolytic enzymes,
phosphofructokinase (PFK) and pyruvate kinase (PK) in a
concentration- and time-dependent manner [45, 46]. Lac-
tate production which reflects the PFK activity, was in-
creased by Zinc [46]. However, the effects of Zinc and
insulin were not additive and Zinc pretreatment prevented
the stimulation of glycolytic enzymes by insulin. Further-
more, in Zinc-treated cells a progressive activation of
ERK2/MAPK1 (Mitogen-activated protein kinase-1) was
observed [45]. However, a recent in-vitro study using
hepatocytes has shown that at sub-lethal concentrations,
ZnO nanoparticles increase both gluconeogenesis and
glycogenolysis, contradicting the finding from the earlier
studies given above [47].
Zinc is also known to be a concentration dependent re-
versible inhibitor of α-glucosidase activity in the intestines
[48, 49]. Zinc binding to α-glucosidase directly induced
tertiary structural changes, however the concentration re-
quired to induce structural changes was greater than that
required to achieve inhibition [49]. In skeletal muscles
Zinc-α2-glycoprotein stimulates the phosphorylation of
AMP-activated protein kinase (AMPKα) and increases
cellular GLUT4 protein [50]. This increase in the expres-
sion of the GLUT4 has also been observed in adipose tis-
sue with resultant increase in glucose uptake [44, 51, 52].
Studies have also shown that whole body as well as adipose
tissue specific insulin sensitivity was positively associated
with Zinc-α2-glycoprotein expression in subcutaneous adi-
pose tissue and that obesity related decrease in Zinc-α2-
glycoprotein is selectively present in subcutaneous but not
in visceral adipose tissue [53]. However, two recent studies
have indicated that Zinc-α2-glycoprotein functions to in-
hibit insulin signaling and, in consequence, insulin-induced
glucose uptake in adipocytes, whereas, Zinc Finger Protein
407 (ZFP407) is known to stimulate GLUT4 mRNA tran-
scription in adipocytes, facilitating insulin-stimulated glu-
cose uptake via GLUT4 [54, 55].
Zinc also enhanced glucose transport in adipocytes
in a dose dependant manner, independent of insulin
[43, 56–58]. Zinc was observed to stimulate the phosphor-
ylation of the IR-ß (Insulin Receptor) subunit [52, 56]. Zinc
also inhibits Glycogen synthase kinase-3 (GSK-3β), which is
a phosphorylating and an inactivating agent of glycogen
synthase, with resultant increase in glycogen synthesis [57].
Furthermore, Zinc-α2-glycoproteins increase the expres-
sion of the lipolytic enzymes, adipose triglyceride lipase
and hormone-sensitive lipase in the white adipose tissue
[51]. Incubation of adipocytes with Zinc, augmented lipo-
genesis and this lipogenic effect was 80 % of maximum
insulin stimulation [43, 59]. In isolated rat liver membrane
cells, Zinc alone stimulated lipogenesis in a dose-related
manner [60].
Treatment of 3 T3-L1 adipocytes with Zinc-chelated
vitamin C (ZnC) has been shown to promote adipogene-
sis, characterized by increased glycerol-3-phosphate
dehydrogenase activity and intracellular lipid accumula-
tion in 3 T3-L1 cells, associated with a pronounced up-
regulation of the expression of glucose transporter type
4 (GLUT4) [61]. ZnC further increased the expression of
peroxisome proliferator-activated receptor gamma (PPARγ)
and CCAAT/enhancer-binding protein alpha, the key tran-
scription factors of adipogenesis [61]. A decrease in insulin
receptor binding has been observed in Zinc deficient rat
adipocytes and addition of Zinc stimulates insulin binding
in a dose-dependent manner [60, 62].
Islet cell function
In-vitro environments increasing the extracellular Zinc
concentration is known to increase the free insulin con-
centration in the immediate vicinity of β-cells, mediated
by enhanced Zinc-insulin dissociation [63]. However, glu-
cose stimulated insulin secretion in β-cells of the pancreas
is inhibited by Zinc, suggesting that co-secreted Zinc acts
in an autocrine inhibitory modulator [64, 65]. In pancre-
atic β-cells of mice and clonal HIT-T15 β-cells, KCl and
glucose induced an increase in free cytosolic Zinc levels,
which facilitated the processing and/or storage of insulin
[66, 67]. This is facilitated by an increase in the expression
of cellular Zinc importers (Slc39a6, Slc39a7, and Slc39a8).
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However, chronic increase in cytosolic Zinc levels follow-
ing sustained hyperglycemia, as in diabetes may contribute
towards β-cell dysfunction and death [66].
Human Islet Amyloid Polypeptide (hIAPP) (a polypep-
tide hormone secreted from pancreatic β-cells in re-
sponse to glucose) and is cleared by the peptidases in
the kidney. hIAPP is known to aggregate in the pancreas
to form dense, insoluble extracellular fibrillar deposit,
causing β-cell destruction in type-2 diabetes [68]. Zinc,
significantly inhibits hIAPP amyloid fibrillogenesis at
concentrations similar to those found in-vivo extracellu-
lar environments [68]. This probably explains the linkage
between the mutations of SLC30A8 zinc transporter
(Zinc Transporter 8 [ZnT8]), which transports Zinc into
the secretory granules, and type-2 diabetes. In human
pancreatic islet cells, ZnT8 is the key protein responsible
for both intracellular Zinc accumulation in insulin-
containing vesicles and regulation of insulin secretion
[69–73]. ZnT8 down regulated cells show reduced insu-
lin content and decreased insulin secretion in response
to hyperglycemic stimuli [74]. However, absence of
ZnT8 expression did not alter rates of insulin biosyn-
thesis, insulin content and glucose metabolism, but con-
tributed to the packaging efficiency of stored insulin
[75–77]. When ZnT8 absent mice were fed a control
diet, glucose tolerance and insulin sensitivity were nor-
mal. However, after high-fat diet feeding, these mice be-
came glucose intolerant or diabetic, and islets became
less responsive to glucose [75]. ZnT8 is down regulated
on exposure to metabolic stress associated with diabetic
and pre-diabetic states, suggesting that it might further
contribute to progression of type-2 diabetes [78, 79]. In
β-cell specific SLC30A8 deficiency (ZnT8 knockout
mice) a low peripheral blood insulin levels was observed,
due to a substantial amount of the insulin being de-
graded during its first passage through the liver [80].
This is possibly due to the low level of Zinc in the portal
circulation co-secreted by β-cells, due to the absence of
ZnT8 (reducing uptake of Zinc by β-cells), which leads to
augmented hepatic insulin clearance. The ZnT8 is also
downregulated in response to exposure of pancreatic β-
cells to hypoxia, resulting in lowered cytosolic Zn2+ con-
centrations [81].
Pancreatic islet cells harvested from rats conditioned
under intermittent hypoxia showed a significant reduc-
tion in Zinc Influx Transporter 8 (ZIP8) expression in
the β-cell membrane, with resultant reduction in cellular
Zinc concentration and insulin production [82]. ZIP6
and ZIP7 function as two important zinc influx trans-
porters to regulate cytosolic Zinc concentrations and in-
sulin secretion in β-cells and ZIP-6 is also capable of
directly interacting with GLP-1R to facilitate the protect-
ive effect of GLP-1 on β-cell survival [83]. Zip4 protein
is located in human pancreatic β-cells, is important for
the accumulation of Zinc in the cytosol and granules of
β-cells [84]. Other Zinc transporters like ZnT3 and ZIP7
might also play a role in insulin secretion and glucose
metabolism [85, 86].
L-type voltage-gated Ca2+ channels and TRMP3 (transi-
ent receptor potential cation channel subfamily M mem-
ber 3) are also in part responsible for Zinc transport into
β-cells, which is also dependent upon the metabolic status
of the cell [87, 88]. Culture of rat pancreatic islets in either
low or high vs. intermediate glucose concentrations trig-
gers early mitochondrial oxidative stress and late β-cell
apoptosis with loss of glucose stimulated insulin secretion
[89]. ZnCl2 reduces mitochondrial oxidative stress and rat
β-cell apoptosis under these culture conditions [89]. ZnO
nanoparticles at dose of 70 ng/mL improved viability and
function of pancreatic islets, by reducing oxidative stress
and preventing cells from entering the apoptotic phase
[90]. It is well known that Reactive Oxygen Species (ROS)
can cause pancreatic β-cell death. This occurs due to the
activation of Transient Receptor Potential Melastatin2
(TRPM2) channels by ROS. TRPM2 causes Ca2+ influx
into the β-cells causing release of lysosomal Zinc,
which results in β-cell death [91]. The tumor suppres-
sor gene ST18 is a neural Zinc finger transcription fac-
tor, expressed in pancreatic β-cells and is known to
impair insulin secretion, induce β-cell apoptosis and
curtail β-cell replication [92].
In glucagon producing α-cells of the pancreas Zinc
accumulates under low and high glucose conditions
through both Ca2+channels and other Zinc transporting
mechanisms, and the intracellular Zinc inhibits gluca-
gon secretion [93]. Furthermore during hypoglycemia
the principal signal that initiates glucagon secretion
could be the detection by α-cells of a sudden decrease
in Zinc paralleling the fall in insulin in the islet peri-
portal circulation and this drop in concentration of
Zinc, closes α-cell ion channels, promoting entry of cal-
cium which stimulates glucagon secretion [94, 95].
Insulin-mimetic compounds
Zinc ions and its’ complexes, have shown insulin-like
action both in-vitro and in-vivo experiments (Table 1)
[96–117]. In-vitro, Zinc complexes inhibit the release of
FFA from cultured rat adipocytes [96–104, 106, 108,
110–112, 114, 116]. In cultured 3 T3-L1 adipocytes
these Zinc complexes activates the insulin signaling
cascade through Akt/PKB (protein-kinase B) phos-
phorylation resulting in GLUT4 translocation to the
plasma membrane and enhanced cellular glucose up-
take [105, 107, 113]. In-vivo type 2 diabetic KK-Ay
mice, these complexes have demonstrated an ability to
reduce blood glucose, HbA1c, triglycerides and total
cholesterol [98, 100, 102, 104, 110–112, 116, 117].
They are also known to improve the glucose tolerance
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Table 1 Summary of Zinc Insulin-mimetic compounds
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Zn(alx)2, Zn(ma)2, Zn(ema)2
and Zn(3 hp)2; Zn(alx)2
exhibited the highest; Zn(alx)2
and Zn(ma)2 induced a
concentration dependent
increase in glucose uptake
Significant insulin-mimetic




KK-Ay mice (i.p. injections
for 14 days); Zn(alx)2 was
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with oral administration (22.3 %)In-vivo—Type 2 diabetic
KK-Ay mice (i.p. injections
for 28 days)
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BW, serum TG and FFA levels
unchanged; TC reduced; Serum






In-vitro—3 T3-L1 adipocytes Zn(opt)2 induced concentration-
and time-dependent Akt/PKB
(protein-kinase B) phosphorylation
and increased GLUT-4 levels in
cell membrane
Zn(opt)2 exhibited insulin-
mimetic activity by activating
insulin signalling cascade
through Akt/PKB phosphorylation













inhibitory effect on FFA release
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even at low doses.
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KK-Ay mice (Oral for
28 days)
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Serum leptin reduced; improved
glucose tolerance with OGTT;
Serum insulin and adiponectin
unchanged
Zn-HTMS has anti-diabetic
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Zn(γ-pga) complex
In-vivo—Type 2 diabetic
KK-Ay mice (Oral for
30 days)
In-vivo—BG lowered to normal;
HbA1c and insulin reduced;
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inhibitory effect on FFA release
Significant insulin-mimetic
properties were exhibited by
Zn(6epa)2In-vivo—Type 2 diabetic
KK-Ay mice (i.p. injections
for 14 days)
In-vivo—BG lowered to normal;
serum TG and TC unchanged;
TC reduced; Serum HbA1c
reduced
Matsumoto,






FFA release; highest activity
Zn(VC)2
A Zn(II) complex with VU or VC
showed preventive effects on





rats (oral, 4 weeks)
In-vivo—Zn(VU)2 Significantly
reduced mesenteric adipocytes
and BG; TC and TG unchanged;
Zn(II)-L-carnitine [Zn(Car)2]
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Table 1 Summary of Zinc Insulin-mimetic compounds (Continued)
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as demonstrated by Oral Glucose Tolerance Testing
(OGTT) [96, 99, 103, 110, 114, 117].
In addition to Zinc containing complexes, Zinc Oxide
nanoparticles (ZnO) are known to posses anti-diabetic
activity. ZnO nanoparticles induce a significant reduction
in blood glucose, elevates serum insulin levels and gluco-
kinase activity, whilst stimulating a higher expression of
insulin, insulin receptor, GLUT-2 and glucokinase genes
in STZ induced (Type-1) diabetic rats [118]. Blood glucose
level is also reduced in Type-2 diabetic rats administered
ZnO nanoparticles, with improved glucose tolerance and
a 70 % increase in serum insulin levels [119]. In addition a
significant lowering of circulating triglycerides and free
fatty acids was also observed suggesting a beneficial effect
of ZnO on lipid metabolism [119].
Other effects
In STZ-diabetes induced mice, Zinc supplementation
has shown to increase the serum leptin concentration
[120]. However, this finding has been contradicted by
several other studies [100, 106, 121]. Hence, although it
is evident that Zinc has an effect on leptin levels, the
exact relationship and mechanisms are yet to be deter-
mined. In-vitro, ZnCl2 is known to stimulate the trans-
differentiation of human heptoma (HpG2) cells into
pancreatic-like cells, with increased expression of amyl-
ase and insulin mRNAs over 1000 and 10 000 fold
respectively [122]. Zinc is also known to activate C-
peptide, with resultant increased energy utilization in
red cells leading to release of ATP, which in turn stimu-
lates NO production in platelets and endothelium caus-
ing reduction in platelet activity [123].
Zinc supplementation has been shown to prevent bone
loss in chronic T1DM rats by stimulating expression of
the mineralizing phenotype in osteoblasts and reducing
expression of the resorptive phenotype in osteoclasts,
achieved by osteocalcin up-regulation and RANKL,
OPG, COL1A, and MMP-9 protein down-regulation
Table 1 Summary of Zinc Insulin-mimetic compounds (Continued)
In-vivo—Type 2 diabetic KK-
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In-vivo—Type 2 diabetic KK-
Ay mice (i.p. injections for





















In-vivo—Type 2 diabetic KK-
Ay mice (oral for 25 days)
(Zn(pdc)2 only)
In-vivo—BG, insulin, HbA1c,













In-vitro—No effect Zn(asp)2 improves insulin
resistance and glucose
tolerance
In-vivo—Type 2 diabetic KK-
Ay mice (i.p. injections for
14 days and oral for
24 days)
In-vivo—BG lowered; improved
glucose tolerance with OGTT;
BG blood glucose; BP blood pressure; FFA free fatty acid; GBA glibenclamide; GLUT glucose transporter; OGTT oral glucose tolerance test; TC total cholesterol;
TG triglycerides
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[124]. Furthermore, in-vitro Zinc inhibited advanced
glycation end product (AGE)-induced MC3T3-E1 cell
(mouse osteoblasts) apoptosis by attenuating the pro-
duction of reactive oxygen species, inhibiting caspase-3
and caspase-9 activation, and inhibiting the release of
cytochrome c from between the mitochondria and the
cytosol [125]. Zinc significantly inhibited AGE formation
of albumin in-vitro and reduced secondary and tertiary
structural modifications of albumin and may have in
controlling/preventing AGEs-mediated diabetic patho-
logical conditions in vivo [126, 127].
Discussion
Numerous in-vitro and in-vivo studies have shown that
Zinc has beneficial effects in both type-1 and type-2 dia-
betes. A finding which has been confirmed by a recent
meta-analysis, where Zinc supplementation resulted in
improved glycaemic control [15]. It is evident from the
findings of the present systematic review, that Zinc plays
an important role in β-cell function, insulin action, glu-
cose homeostasis and the pathogenesis of diabetes and
its complications.
Our results clearly show that Zinc has anti-oxidant
properties and that Zinc supplementation reduces oxida-
tive stress. Zinc supplementation enhances the activity
and levels of key anti-oxidant enzymes and proteins,
whilst significantly reducing lipid peroxidation. Some of
these effects are brought on by interactions at nuclear
level, by stimulation of nuclear factors like Nrf2 [38]. It is
well known that oxidative stress is high in both type-1 and
type-2 diabetic patients, as evident by elevated TBARS
levels in the plasma [11, 19]. This contributes towards fur-
ther β-cell dysfunction, with resultant deterioration of gly-
caemic control. Oxidative stress also plays a pivotal role in
the pathogenesis of both micro- and macro-vascular com-
plications of diabetes [128]. The resultant increase in the
production of ROSs is responsible for the activation of five
major pathways involved in the pathogenesis of diabetes
complications [128]. Increased formation of AGEs, and
the increased expression of the receptor for AGEs and its
activating ligands is one such primary pathway responsible
for the pathogenesis of diabetes related complications
[128]. Both in-vitro and in-vivo Zinc significantly inhibited
the formation of AGEs. Hence, by alleviating the oxi-
dative stress associated with diabetes and by reducing
the formation of AGEs, Zinc supplementation could
delay the progression of diabetes and also delay/pre-
vent the numerous micro- and macro-vascular com-
plications associated with diabetes.
Furthermore, our results show that Zinc plays an
important role in glucose and lipid metabolism. Zinc re-
duces glucose absorption and synthesis, whilst promot-
ing glucose metabolism and storage. This is primarily via
the enhanced activity of key enzymes involved in these
metabolic processes, such as α-glucosidase, PFK, PK and
glycogen synthase. Its insulinomimetic action possibly
mediated via Zinc-α2-glycoporteins increases cellular
GLUT4 levels in skeletal muscles and adipose tissue
facilitating glucose absorption. Zinc-α2-glycoprotein is
gaining increasing recognition as a marker of insulin
resistance in type-2 diabetes. Zinc-α2-glycoproteins are
also involved in lipid metabolism, affecting the expres-
sion of several lipolytic enzymes at hepatic and adipose
tissue level. Two recent meta-analyses have shown that
Zinc supplementation reduces Fasting Blood Glucose,
2 h Post Prandial Blood Glucose and HbA1c in patients
with diabetes, as well as reducing total cholesterol, LDL
cholesterol and triglycerides in both patients with and
without diabetes [15, 129]. The above molecular/enzym-
atic level mechanisms probably explain the beneficial
effects of Zinc supplementation on glycaemic control
and lipids observed in humans.
Zinc also plays an important role in the normal func-
tioning of the islet cells of the pancreas. β-cells and their
granules are extremely rich in Zinc. Zinc Transporters
(ZnTs) transport zinc from the cytoplasm to extracellular
spaces or to intra-cytoplasmic vacuoles, such as secretory
granules, while the ZIPs are thought to increase cytoplas-
mic zinc [130]. Insulin production and efficient packaging
into vesicles is closely linked with the transport of Zinc in
to the β-cells and subsequent concentration inside vesicles
mediated by the Zinc transporter ZnT8, a product of the
SLC30A8 gene, specifically expressed in the β-cells of the
pancreas [131]. Alterations and/or variations in the activ-
ity of ZnT8 is associated with impaired glucose induced
insulin response, which promotes progression from glu-
cose intolerance to type-2 diabetes in susceptible individ-
uals [131]. ZnT8 has also been identified as a novel target
auto-antigen in patients with type-1 diabetes and hence
has diagnostic implications [132]. Auto-antibodies to
ZnT8 (ZnT8A) are detected in 50–60 % of Japanese
patients with acute-onset and 20 % with slow-onset type-1
diabetes [132]. Hence, it is evident that ZnT8 is a key medi-
ator in the pathogenesis of both type-1 and type-2 diabetes.
In addition to ZnT8, altered activity of many other Zinc
transporters and Zinc influx proteins (ZIP 6, 7, 8) have been
implicated in the pathogenesis of diabetes. Zinc is also an
important mediator of α-cell function, as it inhibits gluca-
gon secretion [93]. Identification and characterization of
these ZnTs and ZIPs will help in the development of novel
therapies for diabetes targeting these molecules and to
develop new methods to protect β-cell mass and function,
in both type-1 and type-2 diabetes.
Patients’ adherence to present therapeutic regimes for
diabetes treatment are poor, resulting in unsatisfactory
diabetes control [133]. Regime complexity, hypoglycaemia
and other side-effects, lack of confidence in immediate or
future benefits and patients’ education/beliefs are among
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the common reasons identified that limits adherence
[134–137]. Inadequacies in current treatments has re-
sulted in 2 to 3.6 million people in USA relying on alter-
native therapies for management diabetes [138]. In
addition current treatment modalities are not very effica-
cious in preventing and/or delaying the progression of β-
cell dysfunction and ultimate β-cell failure in patients with
type-2 diabetes. The development of new compounds for
treating diabetes is currently important to reduce the need
for insulin injection in diabetic patients and to replace the
clinically used synthetic therapeutics, which has several
severe side effects [139].
Zinc ions and its’ numerous complexes, have shown
insulin-like action both in-vitro and in-vivo [71–90]. Zinc
complexes activate the insulin signaling cascade via Akt/
PKB, which resultant increase in cellular GLUT4 and
enhanced cellular glucose uptake. In animal models of
type-2 diabetes these complexes have shown a significant
ability to reduce blood glucose, HbA1c, serum insulin,
triglycerides and total cholesterol, whilst improving glu-
cose tolerance. On the basis of these findings and observa-
tions, it is evident that Zinc complexes have promise as a
novel therapeutic modality that mimics the action of insu-
lin [139]. However, presently the findings are only from
in-vitro and in-vivo animal studies, there is a paucity of
data from randomized controlled trials in humans. It is
necessary to identify few efficacious compounds, with the
least amounts of toxicity and for those complexes to be
carefully evaluated in humans. The fruitful outcome of
such trials may offer a novel and effective oral medication
with better anti-diabetic in place of insulin [140].
Conclusion
Numerous in-vitro and in-vivo studies have shown that
Zinc has beneficial effects in both type-1 and type-2
diabetes. It is evident from the findings of the present
systematic review, that Zinc plays an important role in
β-cell function, insulin action, glucose homeostasis and
the pathogenesis of diabetes and its complications. How-
ever further randomized double-blinded placebo-controlled
clinical trials conducted for an adequate duration, are
required to establish therapeutic efficacy and safety in
humans.
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